Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long-term outcomes of tissue-based ACTH-antibody assay-guided transsphenoidal resection of pituitary adenomas in Cushing disease.
|
29027854 |
2018 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In each section, we endeavor to correlate basic mechanisms of ACTH function with the pathological consequences of ACTH signaling deficiency and of overproduction of ACTH.
|
26793988 |
2016 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cushing's disease (CD) is a condition characterized by excess glucocorticoid from an ACTH pituitary adenoma.
|
29716804 |
2018 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
POMC and Tpit mRNA levels were greater in CD and SCA than those in NFT.
|
18057378 |
2007 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Using quantitative real-time PCR, various ACTH-related gene expressions in tumor tissues from CD, subCD, and NFT were measured such as pro-opiomelanocortin (POMC), POMC transcription factor (Tpit, Pitx1, NeuroD1, and Nur77), POMC peptide processing enzymes (prohormone convertase: PC1/3 and PC2), and ACTH secretion-related factors (corticotropin-releasing hormone receptor 1: CRHR1 and glucocorticoid receptor α: GRα).
|
27025408 |
2016 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
|
25942479 |
2015 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACTH = adrenocorticotropic hormone; BIPSS = bilateral inferior petrosal sinus sampling; CBG = corticosteroid-binding globulin; CD = Cushing disease; CRH = corticotropin-releasing hormone; CS = Cushing syndrome; Dex = dexamethasone; DST = dexamethasone suppression test; EAS = ectopic ACTH syndrome; FDA = U.S. Food & Drug Administration; HDDST = high-dose DST; IPS/P = inferior petrosal sinus to peripheral; MRI = magnetic resonance imaging; NET = neuroendocrine tumor; PET = positron emission tomography; UFC = urinary free cortisol.
|
28614036 |
2017 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The selective expression of sst(5) receptors in corticotroph adenomas and the preferential inhibition of ACTH release by human corticotroph adenoma cells by SOM230 in vitro, suggest that SOM230 may have potential in the treatment of patients with pituitary-dependent Cushing's disease.
|
15817922 |
2005 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
This case illustrates that ACTH stimulation by desmopressin is not specific for pituitary-dependent Cushing's syndrome as vasopressin receptor subtypes known to interact with desmopressin may also be found in ectopic tumours producing ACTH.
|
9425403 |
1997 |
Pituitary-dependent Cushing's disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cushing disease (CD) is a rare entity caused by ACTH-secreting pituitary tumours, leading to prolonged hypercortisolism.
|
29927501 |
2018 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The study included adult patients admitted for evaluation of suspected CS (n=85), that were divided into 3 groups: CD (n=22), ACTH-independent CS from an adrenal tumor/hyperplasia (adrenal CS, n=21), and a control group consisting of subjects with negative screening for CS (rule-out CS, n=42).
|
28226363 |
2017 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Higher ACTH levels before treatment predicted a recurrence of CD.
|
28029519 |
2017 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The diagnosis of acromegaly and adrenocorticotropin hormone-dependent Cushing's disease was confirmed.
|
31505284 |
2019 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cushing's disease (CD) is a rare endocrine condition caused by a corticotroph pituitary tumor that produces adrenocorticotropic hormone.
|
31701434 |
2019 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Its diagnosis relies on both biochemical tests (high-dose dexamethasone suppression test, ACTH level, corticotropin-releasing hormone test) to confirm ACTH-dependent CD and image studies (CT or MRI of chest, abdomen, and/or pelvis) for source localization.
|
31019854 |
2019 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to determine the association of hypokalemia with cortisol and ACTH levels in patients with CD.
|
31456238 |
2020 |
Pituitary-dependent Cushing's disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
OBJECT Functional corticotroph pituitary adenomas (PAs) secrete adrenocorticotropic hormone (ACTH) and are the cause of Cushing's disease, which accounts for 70% of all cases of Cushing's syndrome.
|
25639319 |
2015 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cushing's disease (CD) is a spectrum of clinical manifestations due to adrenocorticotropic hormone-secreting pituitary adenoma.
|
31491582 |
2020 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, clinical manifestations of CD may vary depending on hormonal activity; however, factors involved in the hormonal aggressiveness of adrenocorticotropic hormone (ACTH)-secreting pituitary tumors have not been fully clarified.
|
30474823 |
2019 |
Pituitary-dependent Cushing's disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We speculate that the response to the desmopressin test observed in patients with Cushing's disease may be due to abnormal expression of V3R or V2R in ACTH-secreting tumors.
|
8626831 |
1996 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pharmacological targeting of HSF1 may be a promising treatment option for the control of excess ACTH secretion in CD.
|
30995664 |
2019 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
ACTH-dependent hypercortisolism caused by a pituitary adenoma [Cushing's disease (CD)] is the most common cause of endogenous Cushing's syndrome.
|
28382019 |
2017 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, cultures taken from all four ACTH-dependent and the one food-dependent hyperplastic adrenals studied were also responsive to GIP (EC50 for cAMP, 1.3 x 10(-9) M in Cushing's disease and 4.1 x 10(-10) M in food-dependent disease).
|
15705925 |
2005 |
Pituitary-dependent Cushing's disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Exaggerated adrenocorticotropic hormone (ACTH) and cortisol responses to ghrelin in Cushing's disease (CD) have previously been reported, similarly to responses to corticotropin-releasing hormone (CRH).
|
26836811 |
2017 |
Pituitary-dependent Cushing's disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The primary treatment of Cushing disease (hypercortisolism due to ACTH-producing adenomas, which is the cause in approximately 65% of the cases of hypercortisolism) is adenoma resection and medical therapies including ketoconazole, mifepristone, and pasireotide.
|
28170483 |
2017 |